GCLC and cancer: Pre‐clinical and clinical studies suggest that this upregulation might render HIV‐infected and cancer cells more susceptible to pharmacologically induced oxidative bursts, namely through the inhibition of the Nrf2 targets TrxR1 and GCLC (Benhar et al, 2016).